Chapter

Monitoring Treatment Response and Predicting Resistance

From Future of Cancer Science | AACR Cancer Progress Report 2025 by Sambif

Concepts

1. KRAS Profiling

   "Liquid biopsy can also be used to monitor how tumors respond to treatment and to detect the emergence of resistance. Mutations in the KRAS gene are common in colorectal and pancreatic cancers, with G

2. Dynamic Ctdna

   "Monitoring dynamic ctDNA changes during treatment can signal emerging resistance or treatment success. In non–small cell lung cancer, early disappearance of detectable KRAS G12C ctDNA following treat

3. Immune Response

   "Early changes in ctDNA levels after starting treatment have also been used to predict treatment outcome and monitor immune response. In a phase II clinical trial, early changes in tumor-agnostic ctDN